Spotlight On 3 ASX Penny Stocks With Market Caps Over A$10M

In This Article:

The Australian market has shown modest growth, with the ASX200 up 0.3% to 8,488 points, and sectors like IT leading the charge. In this context of sector-specific performance, investors might consider exploring opportunities beyond the well-trodden paths of large-cap stocks. Penny stocks, though an older term, still represent smaller or newer companies that can offer both value and potential growth; here we spotlight three such stocks with noteworthy financial strength in the current market landscape.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Embark Early Education (ASX:EVO)

A$0.78

A$143.12M

★★★★☆☆

LaserBond (ASX:LBL)

A$0.595

A$69.75M

★★★★★★

Helloworld Travel (ASX:HLO)

A$2.01

A$327.26M

★★★★★★

Austin Engineering (ASX:ANG)

A$0.545

A$337.98M

★★★★★☆

MaxiPARTS (ASX:MXI)

A$1.765

A$97.63M

★★★★★★

SHAPE Australia (ASX:SHA)

A$2.75

A$228.01M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.61

A$789.03M

★★★★★☆

Vita Life Sciences (ASX:VLS)

A$2.00

A$112.47M

★★★★★★

Big River Industries (ASX:BRI)

A$1.30

A$110.99M

★★★★★☆

Servcorp (ASX:SRV)

A$4.84

A$477.54M

★★★★☆☆

Click here to see the full list of 1,045 stocks from our ASX Penny Stocks screener.

Let's review some notable picks from our screened stocks.

Battery Age Minerals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Battery Age Minerals Ltd is a battery mineral company with a market capitalization of A$12.58 million.

Operations: Currently, there are no reported revenue segments for Battery Age Minerals Ltd.

Market Cap: A$12.58M

Battery Age Minerals Ltd, with a market capitalization of A$12.58 million, remains pre-revenue and unprofitable, though it has reduced losses over the past five years by 14.1% annually. The company recently raised A$1 million through a follow-on equity offering, boosting its cash position to cover short-term liabilities and improve its cash runway beyond the initial three months reported as of June 2024. Despite having more cash than total debt and positive shareholder equity after past negative figures, the company's high share price volatility and inexperienced board present potential risks for investors in this speculative sector.

ASX:BM8 Debt to Equity History and Analysis as at Dec 2024
ASX:BM8 Debt to Equity History and Analysis as at Dec 2024

EZZ Life Science Holdings

Simply Wall St Financial Health Rating: ★★★★★★

Overview: EZZ Life Science Holdings Limited formulates, produces, markets, and sells health and wellbeing products in Australia, New Zealand, Mainland China, and internationally with a market cap of A$119.55 million.